NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Bioo Scientific

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Bioo Scientific Launches Transduction Reagents for Targeted Delivery into Neuronal and Myeloid Cells - Bioo Scientific’s proprietary MyeloAim™ and NeuroAim™ Transduction Reagents offer targeted delivery of RNAi agents into myeloid and neuronal cells - BiooScientific.com
Bioo Scientific Launches Transduction Reagents for Targeted Delivery into Neuronal and Myeloid Cells

 

NewswireTODAY - /newswire/ - Austin, TX, United States, 2012/04/24 - Bioo Scientific’s proprietary MyeloAim™ and NeuroAim™ Transduction Reagents offer targeted delivery of RNAi agents into myeloid and neuronal cells - BiooScientific.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Bioo Scientific announced today that it has launched the proprietary MyeloAim™ and NeuroAim™ Transduction Reagents which offer directed delivery of RNAi agents into myeloid cells (both in primary cells and in cell lines) or into neuronal cells (both in primary cells and in cell lines) respectfully.

These transduction reagents are able to transduce siRNA to targeted cells both in vitro and in vivo resulting in efficient gene silencing in cells of human, mouse, and rat origin. The MyeloAim™ and NeuroAim™ Transduction Reagents provide a safe and noninvasive approach for the delivery of siRNA and potentially other therapeutic molecules to these cells.

According to Dr. Sandesh Subramanya, Senior Scientist at Bioo Scientific,“The NeuroAim and MyeloAim transduction reagents are the only delivery vehicles available in the market for cell-specific delivery of siRNA and miRNA. These are valuable tools for researchers that focus on studies that require delivering therapeutic small RNAs to neuronal cells and myeloid cells. A huge advantage here is that all payload can ‘selectively hit the mark’ by minimizing targeting to non-specific tissues and cells, be well tolerated, and provide a high therapeutic index.”

About Bioo Scientific Corporation

Founded in 2003, Bioo Scientific Corporation (biooscientific.com) is an Austin, TX based biotechnology company that provides innovative solutions to the life science and food safety industries. Bioo Scientific’s products are used around the world and can be purchased both directly or through our global distribution network that markets our products in more than 100 countries.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Bioo Scientific

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bioo Scientific Launches Transduction Reagents for Targeted Delivery into Neuronal and Myeloid Cells

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Dawn Obermoeller - BiooScientific.com 
512-707-8993 dawno[.]biooscientific.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bioo Scientific securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Bioo Scientific / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

ONO PHARMA Presents Positive Results from Pivotal Trial in U.S. Patients with Relapsed or Refractory PCNSL At 2025 ASCO Annual Meeting
SCHOTT Pharma Expands Ready-to-use Portfolio with Sterile 1.5 ml Cartridge
Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics
SCHOTT Pharma Opens Production Facility in Serbia to Strengthen Competitiveness in Europe
NEC Has Developed Technologies that Enable A Secure Workflow for Personalized Cancer Vaccines and Has Proven their Capabilities
BASF Aroma Ingredients Innovates with Two New Isobionics® Biotech Flavor Ingredients
Federal Government Invests .9 Million in STEMCELL Technologies Canada, Inc.
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
Boehringer Ingelheim Partners with Veeva to Launch ‘One Medicine Platform’
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab & hyaluronidase-nvhy) Injection
NEC Announces Interim Results from Phase 1 Clinical Trial of NECVAX-NEO1
SCHOTT Pharma Unveils Innovative Nest Design for Ready-to-use Cartridges
Ipsen and Biomunex Announce Exclusive Global Licensing Agreement for First-in-class MAIT Cell Engager in Immuno-oncology
Bushu Pharma Applauded by Frost & Sullivan for Offering Customer Value in APAC CDMO Industry through Consistent Quality Assurance, On-time Delivery

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow, Inc.





 
  ©2005-2025 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)